KO Pharma Client Okogen Secures $3.3M Series B Funding

KO client Okogen, a clinical stage ophthalmic pharmaceutical company specializing in innovative eyecare solutions, recently announced the successful closing of $3.3 million in financing.

According to the announcement, the funding will advance the company through the completion of the Phase 2b clinical program for acute infectious conjunctivitis (AIC) and the development of an AI-driven image-based evaluation platform designed for telehealth and at home application.

“We are excited to announce the completion of our latest financing and the launch of our AI-enabled platform,” said Joshua Moriarty, CEO of Okogen, in the announcement. “This milestone reinforces our commitment to delivering comprehensive therapeutic solutions for patients suffering from AIC. Our focus remains on developing innovative, first-in-class products that improve outcomes for patients and efficiency for providers alike.”

KO attorneys Ian Kuliasha, Brooke Eckert, and paralegal Caitlyn Knudson represented Okogen in the financing. Learn more in the announcement.